Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CORDRAN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CORDRAN N.
ARAZLO vs CORDRAN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid + Antibiotic